No Picture
Stocks List

Palatin Technologies Inc. (PTN)

Palatin Technologies Inc. (PTN)

Palatin Technologies Inc. (PTN ) has been moving recently as the stock has ascended by 19% in the previous four weeks, and it is as of now exchanging great over its 20-Day SMA. This is a really strong move higher, yet the inquiry that must be on speculators’ brains at this moment is; would this be able to pattern proceed?

While there can be no telling without a doubt, it is unquestionably reassuring that profit gauges have ascended in the previous couple of weeks on the organization, proposing that estimation on PTN is moving in the

Read More
No Picture
Stocks List

Peregrine Pharmaceuticals Inc. (NASDAQ:PPHM)

Peregrine Pharmaceuticals Inc. (NASDAQ:PPHM)

It’s been an unpleasant year for Peregrine Pharmaceuticals Inc. (NASDAQ:PPHM) shareholders. PPHM slammed on 2/26/2016 when the organization’s Phase III trial for Bavituximab (an exploratory hostile to malignancy medication) was ended. Be that as it may, things were not all fate and unhappiness. Another bio-producing office was commisioned on 3/17/2016. While Bavituximab may have hit a deadlock, the Avid Bioservices division is blasting. The new plant dramatically increased Avid’s assembling limit.

The uplifting news for the Avid Bioservices division proceeded with financial Q4 2016 results. Devoted reported a $68 million income overabundance. Fabricating incomes of $50

Read More
No Picture
Stocks List

Oramed Pharmaceuticals, Inc. (NASDAQ:ORMP)

Oramed Pharmaceuticals, Inc. (NASDAQ:ORMP)

An oral insulin tablet could tackle, however for a long time, no organization has made sense of how to even hypothetically regulate insulin orally. That is, as of recently. Oramed Pharmaceuticals, Inc. (NASDAQ:ORMP) has demonstrated on a basic level through a late Phase II concentrate on that insulin can be taken orally in the right plan, and lowers evening time pooled glucose contrasted and fake treatment, at any rate as indicated by one trial.

A bigger Phase III study will need to affirm these discoveries and is at present being arranged, however the essential confirmation is

Read More
No Picture
Stocks List

Northwest Biotherapeutics (NWBO)

Northwest Biotherapeutics (NWBO)

Following a decline of 9.3% amid Northwest Biotherapeutics (NWBO) facilitates all things considered volume in light of its revelation that it reduced the activity costs for certain warrant holders as an instigation to bring ~$1.3M up in new capital.

The organization offered an activity cost of $0.35 an offer for warrants to buy up to 3,656,817 shares of normal stock with unique activity costs of $4.50 – 6.00.

What’s more, Northwest issued new five-year Series E Warrants to the same warrant holders to buy up to 3,656,817 shares of basic stock at $0.41 an offer.

However, the

Read More
No Picture
Penny Stocks Articles

Ocular Therapeutics Continues to Surge despite Headwinds

Ocular Therapeutics Continues to Surge despite Headwinds

Ocular Therapeutics is up 34.8% recently subsequent to declaring that the FDA’s worries with respect to the organization’s New Drug Application (NDA) seem to have been tended to.

Situated in Bedford, MA, OCUL is a biopharmaceutical organization that spotlights on the improvement and commercialization of eye-consideration items. It has created DEXTENZA, a treatment intended to be directed for visual agony taking after eye-related surgery.

The FDA issued a Complete Response Letter (CRL) to the organization’s NDA, refering to worries about insufficiencies in OCUL’s assembling forms that were seen amid an assessment. However there

Read More
No Picture
Penny Stocks Articles

Neuralstem, Inc. (Nasdaq:CUR)

Neuralstem, Inc. (Nasdaq:CUR)

Neuralstem, Inc. (Nasdaq:CUR), a biopharmaceutical organization concentrated on the advancement of focal sensory system treatments in light of its neural undifferentiated organism innovation, reported its money related results and gave business and clinical overhauls to the three and six months time spans finished June 30, 2016.

In the second quarter of 2016, the organization have taken measures to enhance the Company’s cost structure and finished activities to fortify the association, especially with the arrangement of another Scientific Policy Committee.

In Q2, the organization carried clinical headways with its lead compound, NSI-189, and they are satisfied with movement

Read More
No Picture
Stocks List

MiMedx Group Inc (MDXG)

MiMedx Group Inc (MDXG)

MiMedx Group Inc (MDXG) shares exchanged higher after the organization reported strong growth in its second quarter and increased its full year guidance.

The organization said that in light of the quarter-to-date comes about, it sees income between $62 million and $64 million for the second from last quarter. Examiners gauge $63.12 million income. The organization communicated the certainty that the new item dispatches like OrthoFlo would empower it to accomplish the upper end of the income estimate.

For the entire year, MiMedx emphasized its direction of $243.5–$248 million with final quarter income to be exceptionally

Read More
No Picture
Stocks List

Neovasc Inc. (NVCN)

Neovasc Inc. (NVCN)

Starting late, it has certainly been an incredible time to be a financial specialist in Neovasc Inc. (NVCN). The stock has moved higher by 29% in the previous month, while it is likewise over its 20 Day SMA as well. This blend of solid value execution and ideal specialized, could recommend that the stock might be on the right way.

Exercises to build the rate of enrolment of patients in the Tiara clinical system, including new focuses, presenting the 40 mm Tiara and refining incorporation criteria are bringing about an expanded number of implantations. There have now

Read More
No Picture
Penny Stocks Articles

Ligand Pharmaceuticals (NASDAQ:LGND)

Ligand Pharmaceuticals (NASDAQ:LGND)

Financial specialists hoping to partake in the biotech space without going out on a limb related straightforwardly with medication advancement might need to investigate Ligand Pharmaceuticals (NASDAQ:LGND).

The organization depicts itself as a “biopharmaceutical” organization that is centered around creating or gaining advancements that help pharmaceutical organizations find and create drugs. They portray their income model as enhanced and their cost structure low and productive. Their objective for speculators is to offer a lower-hazard venture chance to take part in the guarantee of the biotech business.

Their operations concentrate on medication disclosure, early-arrange drug advancement, item transformation

Read More
No Picture
Stocks List

Marinus Pharmaceuticals, Inc. (MRNS)

Marinus Pharmaceuticals, Inc. (MRNS)

Marinus Pharmaceuticals, Inc. (MRNS ) was a major mover recently, as its shares ascended more than 29%. The move went ahead strong volume too with significantly a greater number of shares changing hands than in an ordinary session. Recent rally proceeds with the late uptrend for the organization, as the stock is currently up more than 55% in the previous one-month time period.

Marinus Pharmaceuticals has been on somewhat of an icy streak of late, however there may be promising end to present circumstances for this ignored stock. What’s more, for specialized financial specialists there is

Read More
No Picture
Stocks List

Mast Therapeutics (NYSEMKT:MSTX)

Mast Therapeutics (NYSEMKT:MSTX)

Mast Therapeutics (NYSEMKT:MSTX) says stage 3 EPIC trial of vepoloxamer, which treats people with sickle cell illness encountering vaso-occlusive emergency, did not meet its essential adequacy endpoint.

Endpoint was measurably huge diminishment in the mean length of VOC (82 hours in the vepoloxamer bunch contrasted with 78 hours in the fake treatment bunch in the plan to-treat populace (p=0.09)). There were no measurably critical contrasts between treatment bunches in the goal to-treat populace over the two optional viability endpoints, rate of re-hospitalization for VOC and the event of intense mid-section disorder.

The Company’s CEO said “We are

Read More